Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pomalyst
Pharma
BMS accused of anticompetitive tactics to keep Pomalyst chugging
Blue Cross and Blue Shield of Louisiana claims the drug giant used sham patents and lawsuits to extend its Pomalyst monopoly.
Zoey Becker
Sep 7, 2023 11:31am
With Revlimid sales down, BMS slashes 2023 revenue projection
Jul 27, 2023 11:43am
J&J's subcutaneous Darzalex triumphs in another phase 3 study
Aug 7, 2020 12:28pm
BMS snags Pomalyst green light in rare AIDS-related skin lesions
May 15, 2020 11:53am
Sanofi's FDA nod for Sarclisa represents a 'return to oncology'
Mar 2, 2020 1:51pm
Celgene's Revlimid, Pomalyst leap ahead on new triple-combo OKs
Jul 30, 2019 12:16pm
